Neumora Therapeutics, Inc.
NMRA
$1.63
$0.010.62%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 8.06% | -1.59% | -3.33% | -89.07% | -108.25% |
Total Depreciation and Amortization | -25.57% | -5.69% | -5.54% | -1.39% | 5.63% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -62.11% | -53.98% | -53.53% | 629.45% | 843.83% |
Change in Net Operating Assets | 201.02% | 429.71% | 354.37% | 1,228.63% | -2,618.75% |
Cash from Operations | 1.34% | -15.15% | -12.04% | -29.42% | -65.01% |
Capital Expenditure | 190.54% | 190.54% | 100.00% | -753.13% | -352.91% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 245.90% | 240.26% | -209.38% | -0.09% | -352.88% |
Cash from Investing | 245.47% | 239.77% | -209.58% | -1.78% | -356.63% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -92.84% | -91.68% | -90.86% | -97.21% | 20,011.07% |
Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 100.00% | 100.00% | 100.00% | 64.66% | -1,107.21% |
Cash from Financing | -84.93% | -91.54% | -90.69% | -97.86% | 106.32% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 48.88% | -100.65% | -274.29% | -185.50% | -279.85% |